TREM1 and Sepsis: Furthermore, macrolide therapy has been shown to lower the serum IL-10 to TNF-α ratio and to promote the production of TNF-α, IL-6, and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) from activated monocytes, indicating a potential role in re-establishing the equilibrium between pro- and anti-inflammatory mediators in sepsis [25].